# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001104659-16-153723
Filing Date
2016-11-01
Accepted
2016-11-01 16:07:17
Documents
9
Period of Report
2016-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | a16-20866_18k.htm | 8-K | 36686
2 | EX-2.1 | a16-20866_1ex2d1.htm | EX-2.1 | 1200404
3 | EX-99.1 | a16-20866_1ex99d1.htm | EX-99.1 | 28976
4 | GRAPHIC | g208661kg31i001.gif | GRAPHIC | 277720
5 | GRAPHIC | g208661kg31i002.gif | GRAPHIC | 422760
6 | GRAPHIC | g208661kg31i003.gif | GRAPHIC | 359939
7 | GRAPHIC | g208661kg31i004.gif | GRAPHIC | 328867
8 | GRAPHIC | g208661kg29i001.jpg | GRAPHIC | 808
9 | GRAPHIC | g208661mmi001.jpg | GRAPHIC | 4864
| Complete submission text file | 0001104659-16-153723.txt |  | 3188243

Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 161964829
SIC: 2835 In Vitro & In Vivo Diagnostic Substances